Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR1006
- Development stage
- Preclinical
- Lead developer
- AriBio
- Modality
- Small Molecules
01
Overview
AR1006 is an investigational natural product-derived therapeutic candidate being developed by AriBio (also known as ARI Biotechnology) for the treatment of Rett Syndrome. Rett Syndrome is a rare, severe genetic neurological disorder that leads to significant cognitive, motor, and autonomic impairments. AR1006 is designed to exert anti-inflammatory effects, specifically targeting neuroinflammation which is a recognized component of the disease's pathology. As of early 2024, the drug is in the IND-enabling stage of development, with the company preparing for initial clinical evaluation to assess its safety and efficacy in mitigating the symptoms and progression of Rett Syndrome.
Beyond the preview
Go deeper on AR1006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR1006.